AbbVie (ABBV) Says IMBRUVICA Combo Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR in Some CLL Patients

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today shared res...